← Simulations Plus overview

Simulations Plus vs Inspire Medical Systems: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Simulations Plus Inc (SLP)

Q3 2026
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

July 2026
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

Latest
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

Inspire Medical Systems Inc (INSP)

Q3 2026
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.

August 2026
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.

Latest
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.